To validate our hypothesis that the tumor-suppressive effect of WSX1 relies on its impact on CD8+ T-cells, we next performed in vivo depletion of CD8+ and CD4+ T-cells as well as NK cells using specific antibodies. The gene discussed is CD8A; the disease is neoplasm.